Literature DB >> 19042019

Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia.

Emmanuelle Tavernier-Tardy1, Jérôme Cornillon, Lydia Campos, Pascale Flandrin, Amélie Duval, Nathalie Nadal, Denis Guyotat.   

Abstract

We analysed, by flow cytometry, the "adhesive" phenotype of acute myelogenous leukemia (AML) cells from 36 patients treated in our institution. In univariate analysis, the main prognostic factor for CR achievement was lower CXCR4 expression (p=0.03). Overall survival (OS) was negatively influenced by higher CXC chemokine receptor 4 (CXCR4) (p=0.01), very late antigen-4 (VLA-4) (p=0.01), and focal adhesion kinase (FAK) expression (p=0.04). Combination of these markers allowed to distinguish two prognostic groups: patients overexpressing 2 or 3 factors had a significantly shorter OS (p=0.015). CXCR4, VLA-4 and FAK are new phenotypic markers which could be helpful to establish risk-stratified therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19042019     DOI: 10.1016/j.leukres.2008.10.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  27 in total

1.  Focal Adhesion Kinase as a Potential Target in AML and MDS.

Authors:  Bing Z Carter; Po Yee Mak; Xiangmeng Wang; Hui Yang; Guillermo Garcia-Manero; Duncan H Mak; Hong Mu; Vivian R Ruvolo; Yihua Qiu; Kevin Coombes; Nianxiang Zhang; Brittany Ragon; David T Weaver; Jonathan A Pachter; Steven Kornblau; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2017-03-07       Impact factor: 6.261

Review 2.  The bone marrow microenvironment and leukemia: biology and therapeutic targeting.

Authors:  Edward Allan R Sison; Patrick Brown
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

3.  High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.

Authors:  Roland B Walter; Todd A Alonzo; Robert B Gerbing; Phoenix A Ho; Franklin O Smith; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Janet L Franklin; Craig A Hurwitz; Michael R Loken; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

Review 4.  The role of molecular tests in acute myelogenous leukemia treatment decisions.

Authors:  Gabriela Motyckova; Richard M Stone
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

5.  High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse.

Authors:  Shabnam Shalapour; Jana Hof; Renate Kirschner-Schwabe; Lorenz Bastian; Cornelia Eckert; Javier Prada; Günter Henze; Arend von Stackelberg; Karl Seeger
Journal:  Haematologica       Date:  2011-08-09       Impact factor: 9.941

6.  Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.

Authors:  Peter Herhaus; Stefan Habringer; Kathrin Philipp-Abbrederis; Tibor Vag; Carlos Gerngross; Margret Schottelius; Julia Slotta-Huspenina; Katja Steiger; Torben Altmann; Tanja Weißer; Sabine Steidle; Markus Schick; Laura Jacobs; Jolanta Slawska; Catharina Müller-Thomas; Mareike Verbeek; Marion Subklewe; Christian Peschel; Hans-Jürgen Wester; Markus Schwaiger; Katharina Götze; Ulrich Keller
Journal:  Haematologica       Date:  2016-05-12       Impact factor: 9.941

7.  β-Arrestin1 and Signal-transducing Adaptor Molecule 1 (STAM1) Cooperate to Promote Focal Adhesion Kinase Autophosphorylation and Chemotaxis via the Chemokine Receptor CXCR4.

Authors:  Olga Alekhina; Adriano Marchese
Journal:  J Biol Chem       Date:  2016-10-27       Impact factor: 5.157

8.  Serum levels of FAK and some of its effectors in adult AML: correlation with prognostic factors and survival.

Authors:  Mona G El-Sisi; Sara M Radwan; Alia M Saeed; Hala O El-Mesallamy
Journal:  Mol Cell Biochem       Date:  2021-01-28       Impact factor: 3.396

9.  CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia.

Authors:  L Brault; A Rovó; S Decker; C Dierks; A Tzankov; J Schwaller
Journal:  Leukemia       Date:  2013-07-02       Impact factor: 11.528

10.  The use of covalently immobilized stem cell factor to selectively affect hematopoietic stem cell activity within a gelatin hydrogel.

Authors:  Bhushan P Mahadik; Sara Pedron Haba; Luke J Skertich; Brendan A C Harley
Journal:  Biomaterials       Date:  2015-07-23       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.